^(125)I-抗AFP抗体介入灌注联合化疗栓塞治疗肝癌的临床观察

The Effect of Infusion ^(125)I-antiAFP Antibody via Hepatic Artery Combined with Chemo-embolization in Patients with Hepatocellular Carcinoma

目的 观察12 5I 抗AFP抗体经肝动脉灌注后在癌灶内的定位导向能力及与化疗栓塞(TACE)联合治疗肝癌的近期疗效和毒副作用。方法 肝动脉内介入灌注12 5I 抗AFP抗体联合行TACE ,综合治疗肝癌 36例。结果 导向组瘤 肝放射比值平均为 1 86± 0 72 ,有效率、AFP显著下降率及中位缓解期与TACE组相比 ,各为 55 6 %比 4 1 2 % (P >0 0 5)、77 8%比 52 9% (P <0 0 5)、8 5M比 5 6M(P <0 0 5)。两组的毒性反应相似。结论 经肝动脉灌注并与TACE联合可显著增强12 5I 抗AFP抗体在肝癌灶中的导向定位能力和滞留能力及内照射作用 ,提高综合疗效。

Objective To evaluate the hysteresis of 125 Ⅰ antiAFP antibody infused via hepatic artery combined with TACE in patients with HCC,and the effect and toxicity were observed.Methods In targetting therapy group (36 cases), 125 Ⅰ antiAFP antibody was given as an intrahepatic artery infusion combined with TACE.34 cases reseived TACE alone group.Results Medium radioactive ratio of tumor/liver was 1 86±0 72 after targetting therapy.Response rate (PR+MR) were 55 6% and 41 2% for targetting therapy group and TACE alone group,respectively ( P >0 05).Markedly reduced rate of serm AFP level and medium duration of response were 77 8% and 8 5%M for targetting therapy group and 52 9% and 5 6M for TACE alone group,respectively ( P <0 05).Transient hypothyronine T 3 and T 4 occurred in 16 7% cases of targetting therapy group.The other toxicities were tolerable and similar in two groups.Conclusion 125 Ⅰ antiAFP antibody infusion via hepatic artery combined with TACE have a specific retentionist in the tumor mass.The efficacies of complex therapy were better than TACE alone for HCC,and the toxicities were tolerable.